The Skinny on the deal According to the terms of the deal, as reported by Axios, the two pharmaceutical giants will sell their weight-loss drugs to the Medicare programs for $245 a month to treat both diabetes and obesity
But beneath the surface of glossy marketing and fitness fantasies lies a far more sobering truth: many of these substances operate in a medical grey zone, with unknown long-term risks, questionable manufacturing standards, and in some cases, life-threatening side-effects
Let them know that they could be paying less for them
[M]any people lose years trying medications when surgery would have given them a better long-term outcome, he said
This unique presentation of both NAWE and TIND in a single patient following GLP-1 agonist use warrants careful consideration of the potential central and peripheral neurological sequelae of these increasingly prevalent medications and emphasizes the need for heightened clinical awareness and appropriate monitoring strategies
Never use or charge a damaged or swollen battery